

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Cenobamate for focal onset seizures in epilepsy [ID1553]

Batch 72

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

At consultation, the Association of British Neurologists commented: “Consider: Children/ adolescents, Pregnancy, Elderly. In particular use of this drug in patients with intellectual disability (ID) and impact of such a drug on those with known mental health disorders.”

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

These groups (pregnant women, elderly, people with intellectual disability and mental health disorders) are currently included in the scope and it is not the intention to exclude any groups covered by the protected characteristics. Only children are excluded as there are not covered by the marketing authorisation.

NICE clinical guideline 137 ([CG137](#)) ‘Epilepsies: diagnosis and management’ recommends treatment to be similar to the general population for elderly and people with intellectual disability. For pregnant women, it recommends not to offer sodium valproate unless other options are ineffective or not tolerated and the pregnancy prevention programme is in place.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No.

Approved by Associate Director (name): Nicole Elliott...

Date: 21/09/2020